In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Takeda buys Inviragen for $35mm plus up to $215mm in earn-outs

Executive Summary

Takeda Pharmaceutical Co. Ltd. is continuing to grow its vaccines business, this time through the acquisition of Inviragen Inc., a privately owned biotech with projects in preclinical through Phase II trials for various infectious diseases. Takeda paid $35mm in cash up front, and could hand over up to an additional $215mm in development and commercialization earn-outs.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies